When should you use caplacizumab in the treatment of acute TTP patients?

Whenever I encounter a patient with features of thrombotic microangiopathy and a normal coagulation panel (that rules out DIC), I consider the possibility they may have immune TTP.

If my suspicion of immune TTP is high (e.g. history of autoimmune disease, possible relapse of immune TTP) and there is ...

Just so that all the bases are covered, caplacizumab is indicated only for the use of immune TTP (iTTP), not congenital TTP.

Even with immediate recognition and initiation of TPE and steroids, there is still an appreciable fatality rate with an acute episode of iTTP. Therefore, if it is known that t...